The Covid-19 pandemic has disrupted important cancer treatments.The next global health crisis awaits

The full impact of the pandemic is not yet known, but the sudden impact of COVID-19 is Already confused Cancer treatment.

Due to the stay-at-home order and fear of being infected with the virus, many people interrupted screening, postponed regular visits, and avoided or delayed seeking care. And without seeing a doctor, cancer patients have been unable to benefit from the phenomenal advances in oncology over the last few decades, reducing survival and early diagnosis.

The times of adversity, especially now, offer opportunities for innovation and collaboration. As cancer screening, diagnosis, and treatment continue to advance, the global cancer community will gain the weapon of new tools to not only reverse these declines, but also accelerate their progress.

Prior to the pandemic, cancer mortality was declining at a promising rate. Cancer deaths were seen in the United States from 1991 to 2017 29% decrease.. Cancer mortality in the EU from 2014 to 2019 Continued to fall For both men and women. With increased and accelerated screening, coupled with enhanced diagnostic techniques and breakthroughs in personalized tailor-made treatment, more patients will understand cancer diagnosis faster and have faster access to the care they need. It is now possible.

However, despite many of these advances, the global instability faced with COVID-19 has brought dramatic disruption to the screening and treatment of critical cancers.

Recent research from the American Cancer Society Cancer Action Network report As a result of COVID-19, more than three-quarters of people who are actively receiving treatment for cancer had to delay some aspects of treatment. In addition, the National Cancer Institute has only reduced screening for breast and colorectal cancer. Up to 10,000 additional deaths In the next 10 years.

We know early diagnosis Improve Survival rate. Early detection of cancer gives patients more treatment options and less complex care, which not only benefits patients, but also enables cheaper care. Save money and resources for the entire medical system.. More than ever, the global cancer community needs to come together, re-prioritize screening, and minimize retreat to the healthcare system and society.Considering lung cancer as an example, this disease is It kills 1.8 million people every year World wide. It also bears the heaviest financial burden of all cancers – About 19 billion euros are spent each year About lung cancer only in Europe.Still now, only around 1 in 5 lung cancer patients Diagnosed in stage I.

The “Lung Cancer Screening: Cost of Omission” In a report produced for the Lung Ambition Alliance, target screening using low-dose CT (LDCT) scans Significant reduction Increase your chances of survival by reducing the cost burden and increasing the detection of early-stage lung cancer. That’s right One study found In patients with certain risk factors, one life can be saved for every 320 LDCT scans. In this regard, the number of other cancer screenings is much higher, ranging from over 800 for colorectal cancer and 600 to 1,700 for breast cancer.

We have the tools to do this and to successfully perform large-scale lung cancer screening that will help alleviate the confusion of cancer treatment in the event of a future health crisis such as COVID-19. Outlined the strategy. Partnership for Sustainability and Resilience of Healthcare Systems.. Screening can also reduce the financial burden on the medical system – One quote from the U.S. suggests Save $ 26 Billion in Early Cancer Diagnosis. This approach supports the long-term sustainability of both the healthcare system and government in achieving the goal of reducing cancer mortality.

Read again: Omicron can replace other variants of Covid and survive as a common cold: Harvard immunologist Pilai

The speed and agility of the cancer community’s response to COVID-19 provides hope for rapid progress. Together, we have established new partnerships and collaborations, accelerating our collective progress in protecting the healthcare system to reduce premature cancer mortality.

By bringing together expertise from a variety of disciplines, we leverage technological advances to support patients from diagnosis to treatment. Artificial intelligence (AI) is one tool that has already demonstrated promising capabilities towards this goal. AI has been Shown to detect successfully Recent studies have shown that up to 93% of abnormal lung growth occurs. This means significantly improving the ability to identify patients, streamline care channels, and maximize the resources of the healthcare system. At the same time, we are reinventing ways for people to access and deliver healthcare through digital and home healthcare solutions that increase capacity and reduce the burden and cost of healthcare facilities.

Now is the time for healthcare providers, academic institutions, industry, and healthcare organizations around the world to partner to take advantage of the latest scientific advances in oncology in servicing patients. Early detection is essential to ensure the future sustainability and resilience of the healthcare system.

Together we need to commit:

We are at the crossroads of cancer treatment. One route optimizes care and changes the meaning of getting a cancer diagnosis, and the other route exacerbates the setbacks we are currently experiencing. Early detection and prediction are essential to reduce both infectious diseases and cancer. Early detection of cancer needs to be improved to increase the likelihood of prolonging the survival of the patient.

By following this path, you can prevent one health crisis from spurring another.

this article Originally announced at the World Economic Forum.

Read again: Max Healthcare will invest Rs 3,400 to double India’s production capacity over the next four years